Mode
Text Size
Log in / Sign up

Systematic Review and Network Meta-Analysis Compares Enteral Nutrition and Medications in Pediatric Crohn's DiseaseExclusive nutrition therapy beats steroids for healing Crohn's in kids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider enteral nutrition for induction in pediatric Crohn's disease; evidence shows superiority over corticosteroids.

This systematic review and network meta-analysis synthesized data from 1,182 patients with pediatric Crohn's disease to compare enteral nutrition strategies against immunomodulators and corticosteroids. The authors evaluated clinical remission induction, mucosal healing, and maintenance outcomes across various nutritional and pharmacological interventions within the pediatric population.

Regarding induction, exclusive enteral nutrition was significantly superior to corticosteroids for clinical remission with an odds ratio of 1.72 (95% CI 1.18–2.52). For mucosal healing, exclusive enteral nutrition demonstrated marked superiority versus corticosteroids with an odds ratio of 7.55 (95% CI 3.59-15.88). SUCRA rankings placed CDED plus PEN at 0.80 and exclusive enteral nutrition at 0.78 for remission induction, while corticosteroids ranked lowest at 0.31.

Safety data indicated serious adverse events ranged from 0%–3.1% for enteral nutrition therapies compared to 15.1% for corticosteroids and 11.8% for azathioprine or 6-mercaptopurine. Notably, these safety profiles differ between nutritional and pharmacological approaches. For maintenance, azathioprine or 6-mercaptopurine was superior to placebo with an odds ratio of 12.50 (95% CI 2.47–63.14).

The authors note that these findings support enteral nutrition as first-line induction therapy in pediatric Crohn's disease. However, the review does not report follow-up duration or absolute numbers for all outcomes. Clinicians should interpret these pooled estimates within the context of available evidence and individual patient factors carefully.

For children with Crohn's disease, getting better often means choosing between powerful medicines that cause side effects or dietary changes that actually heal the gut. A major new analysis looked at over 1,182 young patients to see which approach works best. The results offer clear hope for families tired of the trial-and-error process that often defines pediatric Crohn's care.

Exclusive enteral nutrition, or EEN, involves feeding patients a special liquid diet that gives their gut a rest while providing all necessary nutrients. This method was significantly superior to corticosteroids, the traditional first-line treatment, for inducing clinical remission. In fact, it was seven and a half times more effective at achieving mucosal healing, which means the lining of the intestine actually repairs itself.

The study also found that immunomodulators like azathioprine and methotrexate were far better than placebo for maintaining remission. However, the safety profile of nutrition therapy was outstanding, with serious adverse events ranging from zero to just 3.1%. In stark contrast, corticosteroids caused serious issues in 15.1% of cases, and immunomodulators caused them in 11.8% of cases. These findings support using nutrition therapy as a first-line treatment to help children feel better and heal faster.

What this means for you:
Exclusive nutrition therapy works better than steroids for healing Crohn's in kids with fewer side effects.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BackgroundEnteral nutrition (EN) and immunomodulators are established therapies for pediatric Crohn's disease (CD), yet comparative effectiveness data remain limited.ObjectiveWe conducted a network meta-analysis (NMA) to compare the efficacy and safety of EN therapies vs. immunomodulators and corticosteroids for remission induction and maintenance in pediatric CD.MethodsWe systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science from inception through October 2024. Randomized controlled trials (RCTs) and comparative observational studies evaluating exclusive enteral nutrition (EEN), partial enteral nutrition (PEN), Crohn's Disease Exclusion Diet plus PEN (CDED + PEN), supplemental enteral nutrition (SEN), corticosteroids (CS), azathioprine/6-mercaptopurine (AZA/6-MP), or methotrexate (MTX) were included. Primary outcomes were clinical remission and mucosal healing. Frequentist NMA was performed using random-effects models. Surface under the cumulative ranking curve (SUCRA) values determined treatment rankings.ResultsTwenty studies (7 RCTs, 13 observational) comprising 1,182 patients were included. For clinical remission induction, EEN was significantly superior to CS [odds ratio [OR] 1.72; 95% confidence interval [CI] 1.18–2.52; 7 studies; I2 = 0%]. EEN demonstrated marked superiority for mucosal healing vs. CS (OR 7.55; 95% CI 3.59-15.88). SUCRA rankings for remission induction were: CDED + PEN (0.80), EEN (0.78), MTX (0.55), AZA/6-MP (0.47), CS (0.31), and PEN (0.08). For maintenance, AZA/6-MP was superior to placebo (OR 12.50; 95% CI 2.47–63.14). EN therapies exhibited favorable safety profiles with serious adverse event rates of 0%–3.1% compared with 15.1% for CS and 11.8% for AZA/6-MP.ConclusionsEEN and CDED + PEN are the most effective treatments for inducing clinical and endoscopic remission in pediatric CD, with superior safety profiles compared to pharmacological therapies. Immunomodulators remain essential for maintenance therapy. These findings support EN as first-line induction therapy in pediatric CD.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261345561, PROSPERO CRD420261345561.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.